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Abstract
Dendrimers represent a distinct class of polymers—highly branched and uniform, with a 
relatively small size when compared to their mass. They are composed of the core, from 
which branched polymeric dendrons diverge and they are end‐capped with selected ter‐
minal groups. Recently, dendrimers have attracted considerable attention from medici‐
nal chemists, mostly due to their well‐defined and easy‐to‐modify structure. This chapter 
aims to compile dendrimer applications and activities especially for prevention and 
fighting off infections caused by bacteria and fungi, viruses, and parasites/protozoa. Our 
goal in this review is to discuss selected modifications of dendrimers of potential value 
for pharmaceutical chemistry.
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1. Introduction
Dendrimers are spherical nanosized polymers that branch in a well‐defined manner. They 
were first synthesized and described by Franz Vögtle in 1978 [1]. For the last 30 years, they have 
gained a lot of attention, mainly due to the discovery of their stunning complexation abilities. 
In medicinal chemistry, they reveal interesting pharmacological properties of potential value 
for various medical fields. In pharmaceutical sciences, these nanostructures are particularly 
interesting as they can be potentially useful in pharmaceutical technology for preparation of 
water‐soluble complexes with poorly soluble active pharmaceutical ingredients (API). It is 
worth noting that at the same time a decrease in API's overall toxicity is observed.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In this chapter, the aim is to describe the potential use of dendrimers in fighting off infectious 
diseases. Infectious diseases continue to constitute a problem around the globe, and a proper 
surveillance is required, as the amount of reports regarding occurrence of bacteria and fungi 
resistant to all clinically used antibiotics and antimycotics is growing. From one year to the next, 
the number of potentially useful antimicrobials is slowly decreasing, while only a few APIs 
have been introduced to clinical practice in recent years. Therefore, even treatment of common 
diseases has the potential to become a serious problem in the near future. The link between 
pollution and health although complex is obvious. An increasing pollution of the environment 
with pharmaceuticals intended to fight infectious diseases as well as their enhanced consump‐
tion over the last 70 years has led to the development of resistance mechanisms. Additionally, 
the treatment of infectious diseases in developing countries is quite problematic due to the lack 
of regulations in drug marketing. Another factor is the price of what is often referred to as last 
resort medicines; the contribution of public funding is often essential for the implementation 
of therapy with such medicinal products. Moreover, decreased hygiene level and underdevel‐
oped sanitation favour the occurrence of bacterial, fungal and parasitic infections [2, 3].
Currently, the amount of novel antibiotic classes seems to be constant. In parallel, the propa‐
gation of multidrug resistant microbes indicates the necessity of searching for novel agents 
and methods, which can be used as a revolutionary approach. Therefore, present research 
wrestles with the problem of whether novel dendrimer nanoparticles alone or in complexes 
with APIs can be of potential usage in medicinal and pharmaceutical chemistry. The goal is to 
develop novel antibiotics, antimicrobial and antiparasitic/protozoa therapies. Currently, there 
are many ongoing attempts that aim at increasing the efficiency of strategies against bacteria 
and fungi in planktonic and biofilm modes of growth. There are researched methods that lead 
to biofilm growth inhibition, disruption or eradication. These approaches include APIs with 
new mechanisms of action, like enzymes, salts, metal nanoparticles, antibiotics, acids, plant 
extracts or antimicrobial photodynamic therapy. Regarding all this, dendrimers could be a 
material that might help to reach this goal [4].
2. Dendrimer structural versatility
Dendrimers do not form a uniform group based on their chemical structure. They are different 
from other dendritic structures such as dendronic and dendritic surfaces, dendronized poly‐
mers, dendriplexes and dendrigrafts. Schematic representation of dendrimeric nanoparticle, 
which constitutes the main subject of this short review, is presented in Figure 1 [5]. Generally, 
dendrimers are composed of three elements: (i) a core, (ii) branched dendrons and (iii) termi‐
nal groups. They are most commonly synthesized using two different synthetic pathways: (i) 
divergent or (ii) convergent (Figure 2). In the divergent approach, firstly the synthesis of the 
functionalized core (or inner part of the dendrimer) takes part. Then this structure serves as 
a scaffold for the synthesis of higher generation dendrimers. Convergent approach relies on 
the synthesis of dendrons, which can be further attached to the earlier synthesized core. Some 
synthetic chemistry techniques, including click chemistry are especially useful for the synthesis 
of dendrimers [6].
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A system was proposed describing the specific branching architecture of dendrimers, with gen‐
eral abbreviation AB
n
—where n stands for new branches that arise from a node. For example, AB
2
 
and AB3 states for two and three branches outgoing from each node, respectively. For graphical 
description, see Figure 3 [6]. The most common dendrimers that can be found in the literature 
are built of AB
2
 building blocks. Among those to the most popular belong poly(amidoamine)—
PAMAM, poly(propyleneimine)—PPI (also called poly(propyleneamine)—POPAM), carbosi‐
lane and poly(L‐lysine)—PLL dendrimers [7].
The core part of dendrimers may be a variety of molecules—starting with single atoms (like 
nitrogen in some PAMAMs), aliphatic chains, alicyclic or aromatic rings through polyaro‐
matic moieties, inorganic frameworks, and ending with other polymers and peptides. The 
core of a dendrimer can be simply a scaffold to which dendrons are attached. However, in 
some cases, the core is a molecule that expresses its own activity and added dendrons modify 
the periphery of the central molecule, thus affecting its physico‐chemical properties (solu‐
bility, photochemical and electrochemical properties, protection from enzymes, etc.) [8–12]. 
Figure 1. Schematic representation of dendrimer structure.
Figure 2. Schematic representation of convergent (a) and divergent (b) method of dendrimer synthesis.
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Dendrons serve mainly as carriers for other compounds. The controlled release of drugs from 
dendron‐drug complexes can be modulated at certain pH values present in the environment 
of living organisms. An acidic environment is often associated with cancerous tissues, which 
was the subject of research by Wang et al. [13]. In this study, a potent and specific proteasome 
inhibitor bortezomib was released from biocompatible modified PAMAM dendrimer com‐
plex when triggered by the acidic environment of the tumour. End‐group or terminal group 
of a dendrimer is a peripheral functionalization of dendrimer. The outstanding feature that 
makes dendrimers so special is the enormous amount of terminal groups in such a small mol‐
ecule. The number of end‐groups increases in exponential manner while the round molecule 
size increases linearly. This is depicted in Table 1 for PAMAM dendrimer. Quite often the 
structure of end‐groups depends on the synthetic method applied (harsh reaction conditions, 
protective groups) and the nature of the dendrimer building blocks [6].
Dendrimer end‐groups can be easily modified. Modification changes their polarity and solu‐
bility in different solvents. In this way, high toxicity associated with many free amino groups in 
PAMAM and PPI dendrimers may be overcome by substituting them partially with non‐toxic 
moieties [15, 16]. Alternatively, appending the end‐groups with hydrophobic substituents 
may be considered, when they are intended to be utilized as carriers in hydrophobic formu‐
lations. In this way, the toxicity of prepared dendrimer is kept at bay and its complexation 
capabilities in hydrophobic mediums are increased. Utilizing this method, Hamilton et al. [17], 
while studying potential proteomimetics for ophthalmic use, decorated hydroxyl‐terminated 
G5 PAMAM dendrimers with either dodecyl or cholesteryl moieties. Interestingly, use of 
dodecyl chains highly increased the overall molecule toxicity, as assessed on Chinese Hamster 
ovarian cells and pig lens epithelial cells. Cholesteryl‐modified G5 PAMAM expressed toxicity 
to a lesser extent and was less toxic against lens epithelial cells than unmodified dendrimer. 
In another study, appending the hydrophobic Fréchet‐type dendrimers with highly water‐
soluble carboxylic salt groups enabled the use of them in hydrophilic solvents [8].
Alternatively, the end‐groups may be substituted with active substances, targeting molecules 
and others, that are relevant and needed for modern applications. Najlah and D'Emanuele 
reviewed the literature on the subject of dendrimer‐drug conjugates [18]. The main benefit 
Figure 3. Schematic depiction of dendrimer branching modes with examples.
Nanostructured Materials - Fabrication to Applications114
from combining APIs with dendrimers in such manner is that dendrimer‐API conjugates 
are more stable in various conditions as compared to their complexes based on non‐cova‐
lent bonds. A good example for covalent bonding of APIs to dendrimer surface groups is the 
use of dendrimers as carriers for immunoactive peptides in the formation of vaccines. Such 
approach has been successfully tested by Skwarczynski et al. [19]. They have synthesized G1 
triazole‐based dendrons bond to a tetravalent core and with B‐cell epitopes as end‐groups. 
As this structure of amphiphillic properties was introduced to water solution, it assembled to 
form micelles with hydrophobic inner shell and hydrophilic—peptide—outer shell. Another 
type of terminal group modification concerns the use of targeting molecules, such as folic acid 
for cancer cells. Majoros et al. [20] designed and synthesized PAMAM dendrimer that was 
appended with several moieties—covalently bound drug (paclitaxel), target molecule (folic 
acid) and an imaging agent (fluorescein isothiocyanate). It is worth noting that not all terminal 
groups have to be modified at the same time. There are examples in the literature when the 
synthesis of dendrimers was performed in a statistical manner, so that only part of end‐groups 
in dendrimer was modified, while the rest remained unchanged. Alternatively, convergent 
synthetic approach enables to combine various dendrons or polymers into one dendrimeric 
molecule. Such approach was successfully implemented by Albertazzi et al. [21]. Researchers 
managed to obtain hybrid dendritic‐linear block copolymers based on a 4‐arm and 2‐arm 
polyethylene glycol (PEG) core. The 4‐arm‐based dendrimer showed significantly improved 
DNA binding and gene transfection capabilities in comparison with the 2‐arm derivative.
The plethora of different modifications that can be proposed makes dendrimers perfect 
molecules for any chosen application with endless possibilities. For more insight into the 
Dendron 
generation
Number of end‐groups PAMAM dendrimer size [nm]
AB
2
 dendron AB
3
 dendron PAMAM 
dendrimer [7]
Calculated [14] Experimental 
hydrodynamic 
diameter [7]
0 1 1 4 N/A 1.5
1 2 3 8 1.0 2.2
2 4 9 16 1.4 2.9
3 8 27 32 1.6 3.6
4 16 81 64 2.1 4.5
5 32 243 128 2.8 5.4
6 64 729 256 3.6 6.7
7 128 2187 512 4.5 8.1
8 256 6561 1024 5.7 9.7
9 512 19683 2048 6.8 11.4
10 1024 59049 4096 8.6 13.5
Table 1. Number of end‐groups of dendrons for AB
2
, AB3 and PAMAM dendrimers and the size of PAMAM dendrimers.
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potential applications of dendrimers and a broad spectrum of different properties of these 
nanosized polymers, the reader can refer to the comprehensive reviews such as Ref. [5] or Ref. 
[22]. Astruc et al. [5] broadly reviewed dendrimers designed for various functions and they 
discussed many examples of dendrimers and indicated how their physical, photophysical 
and supramolecular properties influence further applications in sensing, catalysis, molecular 
electronics, photonics and nanomedicine. The biomedical applications of dendrimers refer to 
the following areas: drug delivery, boron neutron capture therapy, photodynamic therapy, 
photothermal therapy based on gold and iron oxide nanoparticles, medical diagnostics and 
molecular probes (biosensors). It is worth noting that biomedical applications of dendrimers 
have gained a lot of attention during the last quarter of the century. In addition to dendrimers’ 
own pharmacodynamic properties, especially promising is their possibility to be used as 
nanocarriers of improved solubility in water, biodistribution, ADME profile and pharmacoki‐
netics with many other desired properties including extended circulation time and enhanced 
penetration and retention (EPR) property. Lately, dendrimers have been considered as agents 
of anti‐amyloidogenic potential, as non‐viral vectors of oligonucleotides and siRNA for gene 
therapy purposes and towards detection of IgE‐mediated drug allergy reactions [5].
For pharmaceutical technology, dendrimers are mostly known for their carrier abilities. They 
exhibit great complexation potential for biologically active compounds, drugs, dyes and metal 
ions. Dendrimer carrier abilities for various chemical molecules (drugs, pigments, salts) com‐
prise both drug encapsulation and chemical bonding to the periphery (Figure 4). Dendrimers 
have already found some commercial applications, for example, as a component of sexu‐
ally transferred diseases preventing gel (VivaGel), a non‐viral transfection agent (Superfect) 
and a contrast agent for MRI (Gadomer 17). Regardless of many potential uses and outstand‐
ing properties, there are also some drawbacks associated with dendrimers and their broader 
commercial use—these are usually time‐consuming and expensive synthesis and purification 
of higher generations of dendrimers. Also high concentration of functional groups on the 
periphery debilitates its efficient modification [5, 18].
Figure 4. Dendrimer carrier abilities: (a) compound encapsulation and (b) covalent bonding of compound to the periphery.
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3. Use of dendrimers against infectious diseases
3.1. Dendrimers as antibacterials and antifungals
Therapeutic efficiency of dendrimers as nanocarriers has been proved so far for, for example, 
potent anticancer, nonsteroidal and anti‐inflammatory, antimicrobial and antiviral drugs. In this 
respect, two strategies have been applied for the application of dendrimers as drug carriers. The 
first one was encapsulation of drugs inside dendrimers or their binding to peripheral groups 
of dendrimers by electrostatic or ionic interactions. The second one concerned covalent bond‐
ing of drugs to the periphery of dendrimers [5]. The antibacterial activity of dendrimers has 
been already reviewed by Tülü and Ertürk [23] and Mintzer and co‐workers [24]. The aim was 
to highlight the diversity of dendrimer structural modifications that led to an increased per se 
activity, as well as a decreased toxicity, thus prompting further applications in medical sciences.
Commercially available PAMAM dendrimers are effective antibacterial compounds (Figure 5). 
Amino‐terminated G2 PAMAM dendrimer revealed differentiated minimum inhibitory con‐
centration (MIC) and minimum bactericidal concentration (MBC) activities against various 
strains of Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Salmonella enterica, 
Klebsiella pneumoniae and MDR‐Shigella flexneri. Moreover, it exhibited little toxicity to human 
gastric epithelial cells and did not induce antibiotic resistance in bacteria [25]. Unfortunately, 
due to many amino end‐groups, G3 and higher generation PAMAMs were found to be highly 
toxic to living organisms [25, 26]. To counter this, PAMAM dendrimers were modified in 
other studies with hydroxyl end‐groups or the syntheses were stopped at so‐called half‐gen‐
erations, which resulted in ester group end‐capped dendrons. It was noticed that such end‐
group modifications affect the solubility of the desired dendrimers, while greatly decreasing 
their toxicities and enabling their assessment for potential use in biological systems. Good 
examples in this regard are the studies on PAMAM end‐group modifications by Calabretta 
and co‐workers and Lopez and co‐workers [15, 27]. In these studies, highly toxic G3 and 
Figure 5. Schematic representation of dendrimer action on bacteria and fungi.
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G5 PAMAM dendrimers with amino‐terminated end‐groups were partially substituted with 
poly(ethylene glycol) chains. Such PEGylated dendrimers expressed significantly lower tox‐
icities, while antibacterial activities against Pseudomonas aeruginosa and S. aureus remained at a 
high level. In a similar manner, PAMAM dendrimers up to G4 were appended with aliphatic 
NO‐releasing moieties [28, 29]. Such hybrids were tested on bacterial biofilms of P. aeruginosa 
[28, 29] and S. aureus [28] with positive results. It is worth noting that nitric oxide, which was 
additionally released, increased overall antibacterial activity. In addition, tested dendrimers 
revealed low‐toxicity to mammalian cells.
A highly active but also toxic dendrimer is G4 PPI. Felczak et al. co‐workers overcame its toxic‐
ity by attaching maltose to 25 or 100% of all the amino end‐groups [16]. The modified maltose‐
appended PPI dendrimers were microbiologically assessed against S. aureus, S. epidermidis, 
E. coli, P. aeruginosa, Candida albicans and found to be active against both bacteria and fungi 
with the lowered toxicity assessed against a Chinese hamster fibroblast cell line (B14), human 
liver hepatocellular carcinoma cell line (HepG2), mouse neuroblastoma cell line (N2a) and 
rat liver cell line (BRL‐3A). The PPI G4 dendrimer modified with 25% of maltose was found 
superior to the 100% modified one in terms of antibacterial activity and demonstrated a strik‐
ing selectivity towards S. aureus at the concentrations non‐toxic for eukaryotic cell lines. As 
the continuation of this study, the G4 PPI dendrimer appended in 25% with maltose was used 
in combination with nadifloxacin against Gram‐negative bacteria: E. coli, P. aeruginosa, Proteus 
hauseri revealing an increase in the antibacterial activity of the latter. Similar to the previous 
studies, the tested fluoroquinolone in dendrimer‐complex was found to be less toxic than the 
drug alone [30]. In another study, unmodified G4 PPI complex with ciprofloxacin was found 
to increase quinolone activity at non‐toxic concentrations to mammalian cells [31]. It is worth 
pointing out that other quinolones (nadifloxacin and prulifloxacin) were also complexed with 
dendrimers, like PAMAM (up to the 5th generation) [32]. Although, this combination did not 
enhance the potency of these drugs against E. coli, an increase in their solubility was observed.
Another type of dendrimers, poly(phosphorhydrazone) dendrimers appended with PEG 
chains were synthesized on a solid support provided by silica nanoparticles [33]. These com‐
posites were used for hosting silver‐based nanoparticles and assessed on the basis of their 
antibacterial activity, which was found to reach Gram‐negative (E. coli, P. aeruginosa) and 
Gram‐positive (S. aureus, Enterococcus hirae) bacteria. Wang et al. conducted a similar experi‐
ment, although utilizing titanium dioxide‐supported G5 PAMAMs that were also PEGylated 
[34]. However, no silver addition was needed as the titania‐supported composite tested as 
the thin antibacterial film was found to inhibit growth of S. aureus and P. aeruginosa. Again, 
phosphorus‐containing dendrimers were synthesized by Ciepluch et al. [35] who obtained 
viologen‐phosphorus dendrons (viologen—4,4′‐bipyridinium salts) built around a cyclotri‐
phosphazene core, which were found to be active against Gram positive (S. aureus) and Gram 
negative (E. coli, P. aeruginosa, Proteus vulgaris) bacteria, as well as against C. albicans.
An amino acid‐based dendrimer [36] was found to exhibit low toxicity and high antibacterial 
activity against usually resistant bacterial strains of Acinetobacter baumanii and P. aeruginosa, 
including multidrug‐resistant and extensively drug‐resistant strains. Abd‐El‐Aziz et al. published 
the synthesis of G0‐G2 dendrimers built of melamine core, arene‐cyclopentadienyliron‐based 
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dendrons and piperazine end‐groups [37]. These dendrimers were assessed against drug‐resis‐
tant bacteria methicillin‐resistant S. aureus (MRSA), Staphylococcus warneri and vancomycin‐resis‐
tant Enterococcus faecium (VRE). It is noted that the G2 piperazine end‐capped dendrimer was 
the most active. Interesting in its structure was polyanionic ether‐based G1 dendrimer with lipo‐
philic core, which was highly active against Gram‐positive bacteria—Bacillus subtillis [38]. The 
noteworthy point is that this dendrimer was found to exhibit low toxicity to healthy human cells. 
Carbosilane dendrimers have also been found to be potent antimicrobials. Fuentes‐Paniagua et 
al. synthesized and investigated microbiological evaluation of dendrimers up to the 2nd genera‐
tion with different terminal groups, which revealed promising MIC and MBC values against 
S. aureus and E. coli [39].
Quite a lot of attention has also been given to so‐called antimicrobial peptides. These are 
short, naturally occurring peptides that exhibit high antimicrobial activity. Problems associ‐
ated with the use of these compounds are related to their susceptibility to bacterial enzymes 
and a not fully recognized mechanism of action. Reports published on this subject regarding 
antibacterial activity of synthetic short dendrimeric peptides suggest the high potential of 
such an approach. Lind et al. synthesized modified amino acid‐based low‐generation den‐
drimers [40]. The compounds obtained in this study were assessed for their action against 
S. aureus, E. coli and P. aeruginosa and proven active. At the same time, some hemotoxicity 
was observed. Structurally similar peptide appended PLL dendrimers were the subject of 
a study performed by Bruschi et al. [41] who synthesized a functionalized dendrimer that 
showed promising potential as an antibacterial agent interacting with bacterial lipopolysac‐
charide. It exhibited quite good activity against various Gram‐positive strains and especially 
high activity against Gram‐negative strains with potency similar to lipopeptide antibiotics 
like colistin and polymixin B. One of the most promising activities of dendrimers against 
pathogenic fungi was reported by Staniszewska et al. [42] who designed and synthesized an 
amino acid‐based dendrimer end‐capped with tyrosine moieties for specific action against 
fungi. This dendrimer was found not only to be active against reference and clinical strains 
but also affected the virulence factors of Candida species.
Another approach of utilizing dendrimers in the fight against bacteria is to combine them 
with other structures or compounds. In this way, PAMAMs were combined with multiwalled 
carbon nanotubes and CdS or Ag
2
S quantum dots to form novel hybrid materials [43]. Nano‐
hybrids were found to be highly active against bacteria and the activity was found to be just 
as high or higher than for each component alone. As a continuation of this study, authors 
functionalized the surface of multiwalled carbon nanotubes with polyamide dendrons [44]. 
This composite material was used for synthesis of silver nanoparticles and then applied as a 
carrier for these. Organic–inorganic hybrid was assessed and proven effective as antimicrobial 
against E. coli, P. aeruginosa and S. aureus. PAMAM dendrimers were also numerously tested 
with metals and their ions. The G2 and G3 PAMAMs were utilized as a site for synthesis 
of silver nanoparticles [45]. After grafting cotton with G2 PAMAM‐nanosilver complex, the 
material exhibited bactericidal activity against S. aureus and E. coli. In other studies, utilizing 
polyester dendrimers for nano‐silver formation, it was shown that the antibacterial activity of 
the resulting dendrimer‐silver nanoparticles was strongly dependent on the dendrimer gen‐
eration [46]. Noteworthy is that nanoparticles that were stabilized by dendrimers exhibited 
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no toxic effect on human epithelial cell line A549 as has been proven using 3‐(4,5‐dimethyl‐
thiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. Another nanosized composite was 
developed by Strydom et al. [47]. They synthesized silver sulfadiazine nanoparticles stabilized 
with the addition of G1, G3.5, G4 or G4.5 PAMAM dendrimers. Such nanoparticles in topi‐
cal formulations were evaluated in terms of their antibacterial activity. The use of dendrimers 
improved the activity of resulting material against Staphylococcus spp., E. coli and P. aeruginosa. 
Another interesting work was published by Staneva and co‐workers [48]. They managed to 
append G1 PPI dendrimer with naphthalimide derivative. This nanostructure was found to 
create complex with bivalent ions, such as zinc and copper. Both metal ion complexes exhib‐
ited activity against Gram‐negative and Gram‐positive bacteria, as well as pathogenic fungi. A 
further application of dendrimers was proposed by Zainul Abid and co‐workers, who applied 
PAMAM for water disinfection [49]. The antibacterial activity (E. coli, S. aureus, P. aeruginosa, 
Bacillus subtilis) of the G1 dendrimer was increased by polymerizing it with ethyleneglycol 
dimethacrylate to form polydendrimeric network. The resultant polymer exhibited very high 
antibacterial activity at 10 mg/L in a matter of minutes. The amount of 100% bacteria was eradi‐
cated within 2 minutes of incubation. Gangadharan et al. utilized dendrimers for water disin‐
fection synthesizing them on a solid support [50]. They applied a divergent synthetic pathway 
to dendrimeric poly‐ethylene amine supported on polystyrene copolymer beads and assessed 
its potential activity against both Gram‐positive (S. aureus, B. subtilis) and negative (E. coli, 
P. aeruginosa) bacteria. A decrease in bacterial cell viability was seen, yet the effect was strongly 
dependent on the generation of supported dendrimers and their end‐group functionalization.
Almost all dendrimers described in this chapter derive their high antibacterial and antifungal 
activity from the so‐called starburst effect. Dendrimers mentioned earlier are characterized by 
the exponential growth of the number of terminal groups. Such a rapid increase in the number 
of active sites of small molecules (by means of their volume) is the result of this phenomenon. 
In case of dendrimers as antimicrobial drug carriers, dendrimeric formulations are often just 
as effective or even more so on pathogens as a drug used alone. Use of dendrimers usually 
results in prolonged release of the drug with simultaneously decreased toxicity comparing to 
the parent compound. This can be clearly seen for a plethora of drug molecules. For example, 
such a study was performed for sulfamethoxazole, which is a poorly soluble sulfonamide. Its 
solubility increased in the formulations prepared with PAMAM dendrimers [51]. This increase 
was generation‐dependent. As the result of this change, an increase of sulfamethoxazole anti‐
bacterial activity and sustained release of the drug were observed. Navath et al. carried out a 
study with amoxicillin in modified G4 PAMAM formulation, which was found to be non‐toxic 
and enabled a sustained release of the drug in vitro [52]. The study was enhanced to in vivo 
assessment on pregnant guinea pigs. The intravaginal dendrimer‐amoxicillin biodegradable 
formulation was found not to cause such adverse effects as necrosis or inflammatory response 
in deeper tissues. Also, no pH change in application site was observed nor was any transfer 
across the foetal membranes noticed. Amoxicillin was also the subject of the report by Wrońska 
et al. [53]. However, in this case the G3 PPI, either unmodified or maltose end‐capped was 
studied. Because of toxicity related to unmodified PPI dendrimers, results obtained for maltose 
terminated PPIs are of significance. Antibacterial activity of drugs increased by the application 
of the above mentioned combination. Another drug molecule of antimicrobial activity that was 
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successfully solubilized by PAMAMs was triclosan [54]. Although this formulation has not 
been tested on bacteria, the amount of drug solubilized was remarkable and—as found in this 
report—highly dependent on the pH of the analysed solution. Various interesting topical for‐
mulations were prepared by Wroblewska and Winnicka with the use of erythromycin and G2 
or G3 PAMAM dendrimers [55]. The formulations were optimized and their utility for therapy 
proven by in vitro assessment against Enterococcus faecalis and different strains of S. aureus. 
The same group continued their research with erythromycin and PAMAMs by attempting to 
increase the antibiotic water‐solubility [56]. In this study, PAMAM dendrimers were used to 
solubilize erythromycin and tobramycin to form stable water solutions. While this goal was 
achieved, a slight increase in antibacterial activity against Gram‐positive bacteria (in this case, 
S. aureus and E. faecalis) by means of MBC of solubilized erythromycin was observed. However, 
tobramycin used with dendrimers exhibited unchanged or lower MICs and MBCs when com‐
pared to the drug alone. One of the latest reports describes the development of the G4 PAMAM 
containing lipid hybrid nanoparticle capable of transporting one of the most potent last‐resort 
antibiotics—vancomycin [57]. The results clearly indicate that the use of dendrimer carrier 
increases vancomycin potency against MRSA. Moreover, Skwarczynski et al. developed a G1 
triazole‐based dendrimers, which were end‐capped with B‐cell epitope of Streptococcus pyo-
genes [19]. Such potential vaccine for Straphyloccus infection was found to be self‐adjuvating by 
forming micelle‐like assemblies with dendrimer core, branches in the centre and peptides on 
the periphery. Apart from of immunization properties, the authors suggest, that such approach 
may be applied to other peptides in the preparation of vaccines for various diseases.
3.2. Dendrimers for treatment and prevention of virus‐related infection
Dendrimers have been applied for treatment and prevention of virus‐related infections 
(Figure 6). The best‐known dendrimer acting in an antiviral manner is probably SPL7013, 
discovered by Starpharma, which is the active ingredient of VivaGel [58]. It is a G4 PLL den‐
drimer with functionalized end‐groups used in the form of a gel and marketed as condom 
lubrication. SPL7013 successfully underwent second‐stage clinical trials and was found to 
prevent sexually transmitted diseases, most notably Human immunodeficiency virus 1 (HIV‐1), 
Herpes simplex virus (HSV) and Human papilloma virus (HPV). Recently, Starpharma claimed 
to obtain results indicating prevention of Zika virus infection. Sánchez‐Rodríguez et al. syn‐
thesized second‐generation carbosilane dendrimers, functionalized on the periphery with 
highly anionic sulfonate groups or carboxy groups [59]. Both synthesized dendrimers when 
applied to the vagina‐derived human epithelial VK2/E6E7 cell lines and peripheral blood 
mononuclear cells before exposure to HIV decreased its infectivity. The test conditions also 
included physiological pH to prove their potential utility in protection against in vivo sexually 
transmitted HIV infection. Authors discussed the superior activity of carbosilane dendrimers 
as compared to PAMAMs, as carbosilane dendrimers do not induce inflammatory reaction, 
which influences the infectivity of HIV. Structurally related compounds were also the subject 
of investigation by Vacas‐Córdoba and co‐workers [60]. They synthesized the G1 carbosilane 
dendrimer appended with sulfonated naphthyl groups and G2 carbosilane dendrimer with 
sulphated end‐groups and then assessed their action on HIV and its infectivity. The results 
suggested that developed dendrimers decrease the infectivity rate of pre‐treated peripheral 
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blood mononuclear cells when exposed to the virus. Authors concluded that poly‐anionic den‐
drimers act by electrostatic interaction with HIV proteins inhibiting the ability of the virus to 
bind to target cells and thus its ability to internalize. In addition, the cell‐to‐cell transmission 
was impaired, as assessed in a different test by co‐culturing infected cells with healthy TZM.
bl cells (modified HeLa cell line especially prone to HIV infection). High capability to prevent 
infection by the G1 dendrimer was also presented in the presence of seminal fluid [61].
Carbosilane dendrimers were also investigated in terms of other potential antiviral applications 
[62, 63]. Knowing that dendrimers are excellent non‐viral transfection agents, two polycationic 
G1 carbosilane dendrimers with different cores were assessed for gene therapy in order to inhibit 
the development of ongoing HIV infection. Both dendrimers were found to exhibit properties 
making them suitable for their planned use. Their non‐toxicity was confirmed (MTT assay). 
They were able to form complexes with nucleic acids and—as siRNA complexes—inhibit repli‐
cation of HIV‐1 and affect macrophage response, thus encouraging further study on this subject.
Antiviral PPI dendrimers were also assessed for potential anti‐HIV treatment [64]. In this case, 
dendrimers up to their third generation were modified on the periphery with anionic groups 
such as carboxylate or sulfonate functional groups. Modified dendrimers were used to complex 
bivalent metal ions: Cu2+, Ni2+, Co2+ or Zn2+. Metal complexes were assessed for their HIV infection 
potential applying in vitro models of first and second infection barriers. Complexes exhibited high 
inhibition rates and prevented internalization of HIV‐1. Inhibition of the virus replication was 
also observed. Han et al. synthesized a G3 PLL built on the core of ammonia and functionalized 
with sulphated cellobiose as terminal groups [65]. The dendrimer was found to be non‐toxic and 
Figure 6. Schematic representation of dendrimer action on viruses.
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active against HIV, as revealed by in vitro MTT assay. Replacing ammonia core with long alkyl 
stearylamide chain resulted in obtaining dendrimer with comparable EC50 values [66]. Recently Ceña‐Díez et al. published a review paper dealing with the topic of various dendrimers express‐
ing antiviral activity against heparan sulphate‐related viral diseases caused by HSV, HIV, HPV, 
Hepatitis C virus and Human respiratory syncytial virus [67]. The authors concluded that all the den‐
drimers analysed (i.e. amino acid‐based dendrimers, glycodendrimers, PAMAMs, carbosilane 
dendrimers) were acting by means of preventing the virus entry to the cell.
Dendrimers have been also assessed as potential vaccine carriers. For an excellent review 
on this subject, the paper by Heegaard et al. is recommended [68]. A very interesting study 
on this subject was performed by Chahal et al. who modified a G1 PAMAM dendrimer with 
long aliphatic chains [69]. Such functionalized dendrimer among other vaccine components 
was used to prepare a formulation for transporting mRNA chains. In this way, a vaccine was 
developed that was capable of providing protection with a one‐dose application from H1N1 
influenza virus, Toxoplasma gondii and Ebola virus. This was confirmed by performing in vivo 
experiment and by comparing the results with bare mRNA vaccination. PAMAM formulation 
was proven to increase stability of the vaccine by protecting nucleic acids from RNAses. The 
vaccine was stable even after 30 days of storage. In another study, a vaccine against rabies 
was developed by Ullas et al. [70] who used G3 poly‐ether imine dendrimer to prepare a for‐
mulation of rabies virus glycoprotein gene. The efficiency of the formulation was evaluated 
by measuring the rabies virus neutralizing antibody levels in treated mice. Addition of den‐
drimer resulted in 4.5‐fold greater increase and thus all the mice that underwent rabies virus 
challenge survived, while in the group treated with formulation without dendrimer only 60% 
viability was observed. PLL dendrimers were the subject of research by Blanco et al. to create 
a suitable vaccination for swine from foot‐and‐mouth disease virus [71]. They prepared G0 
and G1 PLL dendrimers with T‐epitope as a core and B‐epitopes as terminal groups. Such 
prepared functionalized dendrimer was found to offer 100% protection in virus challenge.
A quite different approach was undertaken by Yandrapu et al. [72] who exploited the drug 
delivering properties of dendrimers. The G3.5 PAMAM was modified in the periphery with 
cysteamine. Modified dendrimers were loaded with acyclovir, a known antiviral, and assessed 
in vitro by means of drug release and mucoadhesive properties of the formulation. As in most 
cases, use of dendrimer formulation resulted in sustained release of the drug. Although unmod‐
ified dendrimer was characterized by higher acyclovir loading, presence of thiol groups was 
crucial for increase of bio‐adhesion. In a different study, G4 PPI dendrimers were modified in 
the periphery by mannosylation and conjugation with sialic acid [73]. Functionalized dendrimer 
was used as a carrier for zidovudine. This complex was found to be more effective than PPI 
functionalized with only sialic acid or mannose and was also found non‐toxic as well as zidovu‐
dine being released in a prolonged manner. Dendrimers with antimicrobial activity and for vac‐
cination are also of commercial value as can be seen by a number of patents on the subject [74].
3.3. Dendrimers in fighting off the parasitic/protozoa infection
The action of dendrimers on protozoa and parasitic infections is mostly unexplored areas in 
comparison with their antiviral and antibacterial activity (Figure 7). There is also only limited 
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data on the drug delivery of compounds for treating such infections using dendrimer carriers. 
Below is a summary and discussion of some reports on this subject.
Heredero‐Bermejo et al. published a report regarding anti‐trophozoite Acanthamoeba castellanii 
activity of G0 and G1 carbosilane dendrimers with ammonium salts as terminal groups [75]. 
It was found that G1 dendrimer had the best effect on Acanthamoeba, with LD50 at 0.193 μg/μL after 24 hours of exposure.
Sulfadiazine is one of the drugs used for treatment of T. gondii infections. For a more efficient 
method of this drug delivery, Prieto et al. assessed the possibility of using PAMAMs for its 
delivery [76]. They used commercially available G4 and G4.5 PAMAM dendrimers and loaded 
them with sulfadiazine. Such complexes were assessed by means of their drug loading capabil‐
ities, toxicity and in vitro activity. Each dendrimer was complexing up to 30 molecules of drug. 
Dendriplexes decreased the infection, with the highest decrease for G4 PAMAM‐sulfadiazine 
at 30 nM concentration. In toxicity assessment, the G4.5 complex was found non‐toxic, whilst 
G4 (amino end‐capped) was proven toxic at low concentrations, as shown in MTT assay with 
Vero cells and murine macrophage‐like cell line J774. In other studies, researchers focused on 
Amphotericin B (AmB), which is a drug that possesses anti‐leishmanial activity. Jain et al. [77] 
evaluated the G5 PPI with muramyl dipeptide‐modified terminal groups for its potential use 
as AmB carrier for treatment of leishmaniosis. Such formulation was compared to AmB com‐
mercial formulations: Fungizone and AmBisome assessing its toxicity and antiparasitic activity. 
The results indicated that this dendrimer significantly reduced the haemolytic toxicity of AmB 
to human erythrocytes, as well as cytotoxicity against J774A.1 macrophage cell line as shown 
Figure 7. Schematic representation of dendrimer action on parasitic/protozoa infections.
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by results of MTT assay. Simultaneously, G5 PAMAM‐AmB formulation outruns commercial 
formulations, as can be seen in tests against Leishmania donovani. Jain et al. continued their 
efforts for finding a dendrimer capable of delivering AmB [78]. They reported G5 PPI den‐
drimer partially end‐capped with mannose groups. Dendrimer revealed good loading capac‐
ity and AmB release was pH‐dependent, as faster release was observed in acidic conditions. 
Haemolytic toxicity (human erythrocytes) and cytotoxicity (J774A.1 macrophage cell lines in 
MTT assay) of sole dendrimer and AmB‐loaded dendrimer were assessed and the obtained 
data revealed a decreased toxicity of AmB‐dendriplexes, negligible haemotoxicity and no cyto‐
toxicity of dendrimer. Experiments on BALB/c mice were then conducted to determine in vivo 
properties: formulation pharmacokinetics, biodistibution, haematological toxicity and neph‐
rotoxicity. These studies demonstrated that G5 PPI‐mannose conjugate is a low toxic AmB for‐
mulation, providing prolonged release of carried drug. AmB was also the object of interest for 
Daftarian et al. [79]. They prepared G5 PAMAM bound to a targeting peptide—Pan‐DR‐bind‐
ing epitope. Subsequently, such modified dendrimer was complexed with liposomal AmB in 
different ratios. Formation of a desired complex was confirmed by DLS analysis and electron 
microscopy. Cytotoxicity was tested on Hep2 cells and it was proven to be low. An in vitro and 
later in vivo study on infected BALB/c and C57BL mice was performed to assess therapeutic 
efficacy against Leishmania major infection. In the anti‐leishmanial activity assessment, a six‐
fold decrease in AmB dose for the same therapeutic effect was observed. Due to the designed 
peptide terminal groups, AmB was more likely to accumulate in targeted cells.
It is worth noting that Wang et al. prepared a vaccine for Schistosoma japonicum infection [80]. 
To achieve this, they have end‐capped a G4 PAMAM dendrimer with lysine, which greatly 
decreased the cytotoxicity to human kidney transformed cells 293T. The G4 PAMAM‐lysine 
was then used as a carrier for DNA vaccine, namely SjC23, and in vivo assessment on BALB/c 
mice was conducted as a S. japonicum challenge after three prior immunizations. Dendrimer‐
based vaccine was found to reduce worm levels up to 50% and liver eggs by up to 62%.
3.4. Dendrimers for sensing of infective microbes
Dendrimers were also considered as components of microbial sensing devices (Figure 8). Use 
thereof as bacterial and viral presence has been reviewed by Satija et al. [81]. There is still 
not much known regarding fungi sensing, as only few reports have been published to date. 
Castillo et al. developed a system of indirect detection of fungal presence by sensing aflatoxin 
B1—a known fungal toxin [82]. The system was built of gold electrode coupled with sequential 
monolayers of cystamine, glutaraldehyde, G4‐PAMAM, glutaraldehyde and aptamers (syn‐
thetic receptors). Dendrimers used to construct this sensor provided the signal amplification, 
enabling the detection of aflatoxin B1 in the concentration range 0.1–10 nmol. Use of different mycotoxins proved that the detection system was specific only for aflatoxin B1 as the response 
was concentration‐dependent in this case only. The second and last report regarding fungi 
sensing with the help of dendrimers was published by Mejri‐Omrani et al. [83]. The authors 
described a system prepared for detection of ochratoxin A. The sensor was prepared with the 
use of G4 PAMAM dendrimers and found to detect ochratoxin A in concentration up to 5 μg/L 
with detection limit 2 ng/L. Developed sensor utility was confirmed in real food products tests.
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Use of dendrimers for sensing parasitic presence was assessed by Perinoto et al. who devel‐
oped a device suitable for sensing Leishmania infections in infected BALB/c mice serum sam‐
ples [84]. The sensor was built by depositing in sequence several layers of G4 PAMAMs and 
liposomes containing antigenic proteins on a gold electrode. The device was able to detect 
Leishmania amazonensis antibodies in concentration as low as 10⁻5 mg/mL and the specificity 
of the sensor allowed it to distinguish between leishmaniasis and Trypanosoma cruzi infection.
4. Conclusions and perspectives
In recent years, dendrimers, which represent a distinct class of polymers, have gained con‐
siderable attention from medicinal chemists and pharmaceutical technologists, mostly due 
to their known and potential applications for medicine. Although there are still many unre‐
solved issues on the topic of dendrimers, our goal in this review was to discuss selected 
modifications of dendrimers dedicated to the prevention and fighting of infections caused by 
bacteria, fungi, viruses and parasites.
A great increase of dendrimer‐related research is to some extent bound to their commercial 
availability (mostly PAMAMs) as well as novel and efficient methods of their synthesis. In this 
regard, the development and commercial availability of various innovative building blocks for 
the synthesis of full‐grown dendrimers is especially important. Dendrimer chemistry continues 
to develop year by year and many research groups and companies are interested in studying 
their properties and potential uses. In this chapter, many potential and practical applications of 
dendrimers in prevention of diseases, diagnostics of microbes have been discussed.
Based on the reviewed literature, dendrimers have proven to be useful in many ways. The 
starburst effect of nanopolymers obtained is magnified exponentially, resulting in unprec‐
edented outcomes. A plethora of various studies on PAMAMs revealed how the dendrimers 
activity and toxicity changes upon a slight modification in their structure. Formation of den‐
driplexes quite often increases the biological activity of both dendrimer and encapsulated 
drug molecules. Furthermore, discoveries in the field of dendrimers encourage various stud‐
ies in pharmaceutical technology on poor water‐soluble APIs, which otherwise would not 
be considered useful for clinical practice. Moreover, there is still much to be done in regard 
Figure 8. Schematic representation of dendrimer sensing.
Nanostructured Materials - Fabrication to Applications126
to Gram‐negative bacteria. Because of differences in cell wall structure, they are not as sus‐
ceptible to anti‐bacterials and disinfectants as their Gram‐positive counterparts. In addition, 
studies published on dendrimers do not point out their mechanism of action. Based on the 
non‐specific action of dendrimers on bacteria and fungi, one cannot assume that dendrimers 
always exhibit an identical mechanism of action on these organisms.
Only a few reports deal with the subject of infective fungi and there is almost none regarding the 
parasitic and protozoan infections. Systemic fungal infections are on the rise in developed coun‐
tries because of the increasing use of immunosuppressive drugs after transplantations and due 
to opportunistic infections associated with HIV infected people suffering from AIDS. In terms of 
viruses, the research on the application of dendrimers for the improvement of vaccines is very 
important. As for parasites, encouraging are studies aimed at developing diagnostic methods 
for the detection of these organisms. Generally, high possibilities of modifying dendrimer core, 
branches and terminal groups, as well as development of methods on combining them with 
other active moieties make them unique and highly promising molecules for future use.
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